cetuximab

Cetuximab is distributed by Bristol-Myers Squibb in the US and Merck in the rest-of-world. I wonder what they thought of today's announcement?

"...a combination of Cetuximab and a phylomer CPP-Omomyc fusion was more than three times more effective at killing drug resistant breast cancer cells than either of these agents alone."

Sales of Cetuximab (trade name Erbitux) placed it in the top 10 best selling cancer drugs for 2013 and within the top 50 pharmaceutical products. You would think it would generate a little scientific interest if not boardroom interest.

As previously mentioned, however, Genentech may be the Pharma who is most attuned to the announcement and the potential paradigm shift for cancer therapeutics. From a post on the 22 March under the thread valuing PYCs science;
"Arguably the Genentech collaboration has provided access to the right people particularly if relevant data can substantiate the potency of 1746 linked to the small protein Omomyc inhibitor of MYC."

The data from the  pilot study certainly passes the test of relevance.